Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease

NCT05904093 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

25

Enrollment

NIH

Sponsor class

Conditions

Sickle Cell Disease
Hb-SS Disease
Hemoglobin S
Disease Sickle Cell Anemia
Sickle Cell Disorders
Hemoglobin Beta Thalassemia Disease

Interventions

DRUG: Fostamatinib

Sponsor

National Heart, Lung, and Blood Institute (NHLBI)